Session Information

  • WCLC 2020

    2020 World Conference on Lung Cancer

    Conference Program for the 2020 World Conference on Lung Cancer in Singapore


    Presentation Date(s):  
    • January 28 - 31, 2021
    • Total Presentations: 1597

    All times listed are in Singapore time (GMT+8)

    PL - Plenary
    PS - Presidential Symposium
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    IS - Industry Symposium
    JICC - Joint IASLC-CAALC-CSCO Session

Filter Results:

Show Only CME Accredited Sessions

  • +

    IS07 - Industry Symposium Sponsored by Roche: Expert Perspectives on the Management of Lung Cancer

    • 16:45 - 17:45
    • 1/28/2021
    • Location: Industry Symposia Auditorium (via Industry Hub)
    • Not for CME Credit
    • Type: Industry Symposium
    • Track:
    • +

      IS07.02 - Future Directions for Cancer Immunotherapy: Resectable NSCLC and Novel Combinations in Lung Cancer

      17:15 - 17:45  |  Presenter: Ross Soo, Solange Peters, Martin Reck

      • Abstract

      No abstract available for this presentation

  • +

    FP13 - Immunotherapy (Phase II/III Trials)

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Type: Posters (Featured)
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      FP13.02 - Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189

      00:00 - 00:00  |  Presenter: Jhanelle Elaine Gray

      • Abstract

      Loading...

  • +

    FP14 - Targeted Therapy - Clinically Focused

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Type: Posters (Featured)
    • Track: Targeted Therapy - Clinically Focused
    • +

      FP14.12 - Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK–Positive NSCLC Patients: eXalt3.

      00:00 - 00:00  |  Presenter: Yi-long Wu

      • Abstract

      Loading...

  • +

    P01 - Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
    • +

      P01.21 - ANSELMA: Antiangiogenic Second Line Lung Cancer Meta-Analysis on Individual Patient Data in Non-Small Cell Lung Cancer, Again Relevant in ICI Era

      00:00 - 00:00  |  Presenter: Jordi Remon

      • Abstract

      Loading...

  • +

    P75 - Immunotherapy (Phase II/III Trials) - Misc. Topics

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      P75.04 - Advanced Lung Cancer Inflammation Index (ALI), Neutrophil-to-Lymphocyte Ratio (NLR), and PD-(L)1 Inhibitor Efficacy in NSCLC

      00:00 - 00:00  |  Presenter: Petros Christopoulos

      • Abstract

      Loading...

  • +

    P77 - Immunotherapy (Phase II/III Trials) - Combining Different Immunotherapeutic Approaches

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      P77.04 - PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors

      00:00 - 00:00  |  Presenter: David R. Spigel

      • Abstract

      Loading...

  • +

    OA02 - Updates in Locally Advanced NSCLC

    • 09:15 - 10:15
    • 1/29/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Locoregional and Oligometastatic Disease
    • +

      OA02.03 - Pembrolizumab Plus Platinum Chemotherapy and Radiotherapy in Unresectable, Locally Advanced, Stage III NSCLC: KEYNOTE-799

      09:15 - 09:25  |  Presenter: Martin Reck

      • Abstract

      Loading...

  • +

    PS01 - Presidential Symposium (Japanese, Mandarin, Spanish Translation Available)

    • 07:00 - 09:00
    • 1/30/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Plenary
    • Track: N.A.
    • +

      PS01.04 - International Tailored Chemotherapy Adjuvant Trial : ITACA Trial. Final Results

      07:20 - 07:30  |  Presenter: Silvia Novello

      • Abstract

      Loading...

    • +

      PS01.09 - Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598

      08:08 - 08:18  |  Presenter: Michael Boyer

      • Abstract

      Loading...

  • +

    PS02 - Presidential Symposium (Re-Broadcast) (Japanese, Mandarin, Spanish Translation Available)

    • 18:00 - 20:00
    • 1/30/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Plenary
    • Track: N.A.
    • +

      PS02.04 - International Tailored Chemotherapy Adjuvant Trial : ITACA Trial. Final Results

      18:20 - 18:30  |  Presenter: Silvia Novello

      • Abstract

      Loading...

    • +

      PS02.09 - Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo as 1L Therapy for Metastatic NSCLC of PD-L1 TPS ≥50%: KEYNOTE-598

      19:08 - 19:18  |  Presenter: Michael Boyer

      • Abstract

      Loading...

  • +

    OA11 - A Symphony of Progress

    • 15:30 - 16:30
    • 1/31/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Small Cell Lung Cancer/NET
    • +

      OA11.06 - IMpower133: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage Small-Cell Lung Cancer

      16:00 - 16:10  |  Presenter: Martin Reck

      • Abstract

      Loading...